14.28

3.56% -0.4903

Neuropace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

Neuropace Inc stock is traded at $14.28, with a volume of 130.59K. It is down -3.56% in the last 24 hours and down -11.42% over the past month. NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Previous Close:

$14.77

Open:

$14.58

24h Volume:

130.59K

Relative Volume:

0.69

Market Cap:

$490.15M

Revenue:

$99.53M

Net Income/Loss:

$-21.57M

P/E Ratio:

-22.01

EPS:

-0.6488

Net Cash Flow:

$-9.84M

1W Performance:

-4.28%

1M Performance:

-11.42%

6M Performance:

-7.99%

1Y Performance:

+66.40%

1-Day Range:

$14.18

$14.68

1-Week Range:

$14.16

$15.38

52-Week Range:

$8.17

$19.60

Neuropace Inc Stock (NPCE) Company Profile

Name

Neuropace Inc

Sector

Healthcare (1089)

Industry

Medical Devices (141)

Phone

(650) 237-2700

Address

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Employee

220

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

NPCE's Discussions on Twitter

Compare NPCE vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NPCE Neuropace Inc	14.28	506.97M	99.53M	-21.57M	-9.84M	-0.6488
ABT Abbott Laboratories	110.09	192.51B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	331.95	130.11B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	90.59	116.83B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	51.51	75.11B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	90.72	52.80B	6.30B	1.07B	1.09B	1.8406

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-25	Initiated	H.C. Wainwright	Buy
Jan-21-25	Initiated	UBS	Buy
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-30-24	Initiated	Leerink Partners	Outperform
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

Neuropace Inc Stock (NPCE) Latest News

01:17 AM

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Yahoo Finance

01:17 AM

12:59 PM

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance

12:59 PM

08:50 AM

Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock By Investing.com - Investing.com UK

08:50 AM

08:48 AM

Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock - Investing.com

08:48 AM

05:48 AM

GSA Capital Partners LLP Acquires Shares of 115,535 NeuroPace, Inc. $NPCE - marketbeat.com

05:48 AM

Aug 14, 2026

NeuroPace (NPCE): OrbiMed reports 1.51M-share, 4.4% beneficial stake - Stock Titan

Aug 14, 2026

H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Aug 14, 2026

NeuroPace Q2 revenue up 21% to USD 22.8M - Medical Buyer

Aug 14, 2026

Aug 13, 2026